SCHEDULE 13G: Armistice Capital Discloses 9.99% Passive Stake in Processa Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Processa Pharmaceuticals, Inc. as of March 31, 2025, held for investment purposes in the ordinary course of business.

Summary

• Armistice Capital, LLC and Steven Boyd are the reporting persons in this Schedule 13G filing.
• They collectively beneficially own 578,605 shares of Processa Pharmaceuticals, Inc. common stock.
• This ownership represents 9.99% of the total outstanding common stock of Processa Pharmaceuticals, Inc.
• The shares are held with shared voting power and shared dispositive power by both Armistice Capital, LLC and Steven Boyd.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G) and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects, beyond the fact of a significant institutional investment.

Positives

• A significant institutional investor, Armistice Capital, LLC, has taken a substantial 9.99% stake in Processa Pharmaceuticals, Inc., potentially signaling confidence in the company.

Risks

• The filing itself does not detail specific operational or financial risks of Processa Pharmaceuticals, Inc., focusing solely on beneficial ownership disclosure.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing represents a standard disclosure of a significant passive investment by an institutional fund in a publicly traded pharmaceutical company, reflecting an investment decision within the sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which may be viewed as a positive signal.
• Management: Awareness of a notable passive shareholder on the company's register.

Next Steps

• Future amendments to Schedule 13G will be filed if the beneficial ownership percentage of Armistice Capital, LLC and Steven Boyd changes significantly.

Key Dates

Keywords

Processa Pharmaceuticals, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, investment, pharmaceutical